Olaparib plus pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) and/or homologous recombination deficiency (HRD): Initial results of the phase 2 KEYLYNK-007 study.-MedSci.cn

Olaparib plus pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) and/or homologous recombination deficiency (HRD): Initial results of the phase 2 KEYLYNK-007 study.

Maio, M; Shapira-Frommer, R; Yap, TA; Ciuleanu, T; Gomez, H; Hill, A; Lugowska, I; Ozyilkan, O; Vera, K; Im, SA; Kryzhanivska, A; Lysenko, S; Schenker, M; Stemmer, SM; Saraf, S; Cristescu, R; Jin, F; Gozman, A; Quintela-Fandino, M

CANCER RESEARCH, 2021; 81 (13):

科室
- - 订阅+
  - 更多科室
工具
服务